tools
Recursion OS
AI drug discovery and development platform linking biological experiments, computational models, chemistry design, and clinical development.
Recursion OS is Recursion’s proprietary platform for drug discovery and development. It combines automated wet-lab experiments, computational analysis, machine learning models, chemistry design, and clinical development workflows in a feedback loop.
Recursion and its pharmaceutical partners use it to identify biological targets, design molecules, validate candidates, and support clinical trial planning. The site does not show public self-serve plans or pricing, and the platform is not presented as a general-purpose consumer AI tool.
Features
- Maps disease biology with high-dimensional cellular experiments
- Generates digital representations of biological and chemical experiments
- Uses machine learning and purpose-built large language models
- Supports target identification and biological insight generation
- Designs potential medicines with generative de novo chemistry
- Connects automated wet labs with computational analysis
- Supports clinical development and trial enrollment workflows
- Includes Recursion OS 2.0 workflows for biology, design, and clinical development
Use cases
- Identify disease-relevant biological targets
- Design and prioritize potential drug compounds
- Run integrated design-make-test-learn cycles
- Validate computational predictions in automated laboratories
- Select patients and support clinical trial execution
Pros
Cons
Latest updates
- Unlocking the First Neuroscience Target for the Recursion and Genentech Collaboration
Unlocking a neuroscience target for the Recursion and Genentech collaboration.
- New Data’s Not Enough. How Recursion Is Integrating Data Layers to Advance End-to-End Drug Discovery
Integrating data layers to advance end-to-end drug discovery.
- Since Its Inception, Recursion has Been Building the Foundation for the First Virtual Cell
Building the foundation for a virtual cell.
- How a First-of-its-Kind “Microglia Map” from Recursion and Roche and Genentech Could Unlock New Treatments for Neurodegenerative Diseases
A microglia map from Recursion and Roche and Genentech could unlock treatments.
- The Quest for Better Protein-Ligand Interaction Modeling – Improving ML Methods Offer Promise for AI Drug Discovery
Improving ML methods for protein-ligand interaction modeling.
Pricing
- Prices checked
- 2026-10-25